Journal: Cell stem cell

Article Title: Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma.

doi: 10.1016/j.stem.2017.04.009

Figure Lengend Snippet: Figure 7. a-ITGA7 Impairs GBM Tumor Growth and Invasion In Vivo (A) Luciferase activity detected with a Xenogen IVIS 100 small animal in vivo imaging system, 5 days post-sc transplantation of 5 X 105 GSC1-LUC cells in mice either treated with anti-ITGA7 (a-ITGA7) antibody or isotype control (i.p.). (B) Analysis of sc GSC1-LUC tumor growth over time in mice treated either with isotype control or with a-ITGA7 antibody (1.4A12). Shown is the average photon count and SEM of n = 6 mice/group measured by Xenogen IVIS 100small animal in vivo imaging system (***p< 0.001, two-tailed Student’s t test). See also FigureS7. (C) Analyses of the tumor volumes 5 months after ceasing the anti-ITGA7 treatment. Shown is the size of the sc tumors of n = 6 mice/group measured by calliper (**p < 0.01, two-tailed Student’s t test).

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER PE Mouse monoclonal anti EphA2 (clone 371805) R&D Cat#FAB3035P; RRID:AB_11128496 APC Mouse monoclonal anti CD44 BD Biosciences Cat# 560890 Mouse monoclonal anti CD44 (clone DF1485) DAKO Cat#M7082; RRID:AB_2076596 Mouse monoclonal anti ITGA7 Miltenyi Bioteck Cat#130-103-774 Mouse monoclonal anti murine ITGA7 (clone 6A11) Acris Cat#AM20012AF-N; Please See Table S3 for Reverse Phase Protein Microarray Antibodies used N/A N/A Biological Samples GSC (Glioblastoma Stem Cells) (Marziali et al., 2016; Ricci-Vitiani et al., 2008) N/A Chemicals, Peptides, and Recombinant Proteins EGF Peprotech Cat#100-15 bFGF Peprotech Cat#100-18B Apotransferrin Sigma Cat#T2252 Putrescine Sigma Cat#P5780 Sodium Selenite Sigma Cat#S5261 Bovine Serum Albumin Sigma Cat#A2153 Progesterone Sigma Cat#P8783 Insulin Sigma Cat#I3536 HAT Supplement 50X Thermo Scientific Cat#21060017 HT Supplement 100X Thermo Scientific Cat#11067030 BM Condimed H1 Hybridoma Suppl.

Techniques: In Vivo, Luciferase, Activity Assay, In Vivo Imaging, Transplantation Assay, Control, Two Tailed Test

Journal: bioRxiv

Article Title: Molecular aging is the main driver of Parkinson’s Disease

doi: 10.1101/2025.08.27.672359

Figure Lengend Snippet: (A-C) Determination of proteasomal activity of Caspase-like enzymes of full-brain lysates from S1/S2 animals by proteasome activity assay. Comparison of short-, long- and non-expressing animals with (A) 6 M, (B) 16 M and (C) 24 M of age. Luminescence signal (counts per second, CPS) is proportional to proteasomal activity and was normalized to total amount of 20S proteasome determined by Western blot analysis (student’s t-test, ***<0.001, **<0.01; data: mean ± SEM). (D) Top 20 PD Signature genes and 20 randomly sampled genes were used to calculate a Module Score on the human midbrain snRNA-seq dataset Smajic et al., 2022. P values were calculated by Wilcoxon test on sample wise pseudo-bulked samples. Reflecting our finding in mice GABA-Rgs9 Neurons (GABAergic BGNs), the PD Signature is found to be most affecting the GABAergic Neurons in the human midbrain. This effect is not observed in the random control. (E) Heatmap of scaled log2 Fold Changes of genes from the PD Signature that were concordantly changed across mice GABA-Rgs9 synON24M vs synOFF24M, Smajic et al., human PD vs Control in GABAergic neurons, and Martirosyan et al. PD vs Control in GABAergic neurons. We obtained a total of 53 concordant genes, including genes we deemed as central to our PD Signature, such as Ubb, Dynll1, or Calm1.

Article Snippet: For Western blots with the antibody against the 20S proteasome α1/α2/α3/α5/α6/α7 subunits (Santa Cruz), only 12 % polyacrylamide gels and 40 μg protein per sample was used.

Techniques: Activity Assay, Comparison, Expressing, Western Blot, Control